Literature DB >> 30258300

Multiple Endocrine Neoplasia Type 1: A Case Report With Review of Imaging Findings.

Hilary R Keller1, Jessica L Record2, Neil U Lall2.   

Abstract

BACKGROUND: Multiple endocrine neoplasia type 1 (MEN1) is a rare, autosomal dominant inherited syndrome caused by mutations in the MEN1 tumor suppressor gene. The diagnosis is defined clinically by the presence of 2 or more primary MEN1 tumors (parathyroid, anterior pituitary, and pancreatic islet). We describe the case of a patient who presented with classic history and imaging findings for MEN1. CASE REPORT: A male in his early thirties with a history of hyperparathyroidism and a transsphenoidal prolactinoma resection presented years later with abdominal symptoms concerning for Zollinger-Ellison syndrome: worsening epigastric abdominal pain, nausea, vomiting, and diarrhea. Contrast-enhanced computed tomography (CT) of the abdomen revealed hyperenhancing pancreatic lesions and duodenal inflammation, suggesting pancreatic neuroendocrine tumor (gastrinoma) with secondary duodenitis. Bilateral indeterminate hypoattenuating adrenal nodules were also seen on contrast-enhanced CT, and follow-up magnetic resonance imaging confirmed benign adrenal adenomas. Furthermore, thyroid ultrasound and sestamibi scintigraphy revealed a parathyroid adenoma. With confirmatory imaging findings, history, and presenting symptoms, the patient was clinically diagnosed with MEN1 syndrome and underwent surgical and medical management.
CONCLUSION: This case exhibits the classic history with corresponding imaging findings of MEN1 syndrome, including pancreatic neuroendocrine tumors, parathyroid adenoma, and adrenal adenomas. High clinical suspicion for MEN1 should lead to endocrinology evaluation with appropriate laboratory workup and targeted imaging evaluation of the typical endocrine organs as described for this patient.

Entities:  

Keywords:  Adrenal gland neoplasms; Zollinger-Ellison syndrome; gastrinoma; multiple endocrine neoplasia type 1; neuroendocrine tumors; parathyroid neoplasms; pituitary neoplasms

Year:  2018        PMID: 30258300      PMCID: PMC6135292          DOI: 10.31486/toj.17.0019

Source DB:  PubMed          Journal:  Ochsner J        ISSN: 1524-5012


  21 in total

1.  ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms.

Authors:  G Delle Fave; D O'Toole; A Sundin; B Taal; P Ferolla; J K Ramage; D Ferone; T Ito; W Weber; Z Zheng-Pei; W W De Herder; A Pascher; P Ruszniewski
Journal:  Neuroendocrinology       Date:  2016-01-19       Impact factor: 4.914

Review 2.  Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management.

Authors:  Tetsuhide Ito; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2017-02       Impact factor: 3.243

3.  Long-term outcomes in patients with multiple endocrine neoplasia type 1 and pancreaticoduodenal neuroendocrine tumours.

Authors:  D Donegan; N Singh Ospina; R Rodriguez-Gutierrez; Z Al-Hilli; G B Thompson; B L Clarke; W F Young
Journal:  Clin Endocrinol (Oxf)       Date:  2016-11-17       Impact factor: 3.478

4.  Regional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs).

Authors:  Yassar M Hashim; Kathryn M Trinkaus; David C Linehan; Steven S Strasberg; Ryan C Fields; Dengfeng Cao; William G Hawkins
Journal:  Ann Surg       Date:  2014-02       Impact factor: 12.969

Review 5.  Neuroendocrine pancreatic tumors: guidelines for management and update.

Authors:  William R Burns; Barish H Edil
Journal:  Curr Treat Options Oncol       Date:  2012-03

6.  Adrenal involvement in multiple endocrine neoplasia type 1.

Authors:  Peter Langer; Kenko Cupisti; Detlef K Bartsch; Christoph Nies; Peter E Goretzki; Matthias Rothmund; Hans D Röher
Journal:  World J Surg       Date:  2002-05-21       Impact factor: 3.352

7.  Lanreotide in metastatic enteropancreatic neuroendocrine tumors.

Authors:  Martyn E Caplin; Marianne Pavel; Jarosław B Ćwikła; Alexandria T Phan; Markus Raderer; Eva Sedláčková; Guillaume Cadiot; Edward M Wolin; Jaume Capdevila; Lucy Wall; Guido Rindi; Alison Langley; Séverine Martinez; Joëlle Blumberg; Philippe Ruszniewski
Journal:  N Engl J Med       Date:  2014-07-17       Impact factor: 91.245

Review 8.  Scintigraphic imaging of body neuroendocrine tumors.

Authors:  Charles M Intenzo; Serge Jabbour; Henry C Lin; Jeffrey L Miller; Sung M Kim; David M Capuzzi; Edith P Mitchell
Journal:  Radiographics       Date:  2007 Sep-Oct       Impact factor: 5.333

Review 9.  Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4).

Authors:  Rajesh V Thakker
Journal:  Mol Cell Endocrinol       Date:  2013-08-08       Impact factor: 4.102

10.  A Pilot Comparison of 18F-fluorocholine PET/CT, Ultrasonography and 123I/99mTc-sestaMIBI Dual-Phase Dual-Isotope Scintigraphy in the Preoperative Localization of Hyperfunctioning Parathyroid Glands in Primary or Secondary Hyperparathyroidism: Influence of Thyroid Anomalies.

Authors:  Laure Michaud; Sona Balogova; Alice Burgess; Jessica Ohnona; Virginie Huchet; Khaldoun Kerrou; Marine Lefèvre; Marc Tassart; Françoise Montravers; Sophie Périé; Jean-Noël Talbot
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.